1	Human Postprandial Responses to Food and Potential for Precision
2	Nutrition
3	
4	
5 6	Sarah E. Berry# ¹ , Ana M. Valdes*# ^{3,4,} David A. Drew ⁵ , Francesco Asnicar ⁶ , Mohsen Mazidi ² , Jonathan
7	Wolf ⁷ , Joan Capdevila ⁷ , George Hadjigeorgiou ⁷ , Richard Davies ⁷ , Haya Al Khatib ^{1,7} , Christopher
8	Bonnett ⁷ , Sajaysurya Ganesh ⁷ , Elco Bakker ⁷ , Deborah Hart ² , Massimo Mangino ² , Jordi Merino ⁵ , Inbar
9	Linenberg ⁷ , Patrick Wyatt ⁷ , Jose M. Ordovas ⁸ , Christopher D. Gardner ⁹ , Linda M. Delahanty ⁵ , Andrew
10	T. Chan ⁵ , Nicola Segata ⁶ #, Paul W. Franks ^{2,10, 11} #, Tim D. Spector*# ²
11 12	#joint contributions
13	
14 15	Author affiliations 1 Dept of Nutrition, King's College London, London, UK
16	2 Dept of Twin Research, King's College London, London UK,
17	3 School of Medicine, University of Nottingham, Nottingham, UK
18	4 Nottingham NIHR Biomedical Research Centre, Nottingham UK
19	5 Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
20	6 University of Trento, Trento, Italy
21	7 Zoe Global Ltd, London, UK
22	8 JM-USDA-HNRCA at Tufts University, Boston, MA, USA
23	9 University of Stanford, Stanford, CA, USA
24	10 Department of Clinical Sciences, Lund University, Malmö, Sweden
25	11 Dept of Nutrition, Harvard Chan School of Public Health, Boston, MA, USA
26	
27	*Corresponding Authors:
28	Contact details: Ana M Valdes, PhD, School of Medicine, University of Nottingham, Clinical Sci Bldg
29	City Hospital, Hucknall Rd NG5 1PB, Nottingham, UK, <u>ana.valdes@nottingham.ac.uk</u> ; Tim D Spector,
30	Dept of Twin Research, King's College London, St Thomas' Hospital, Westminster Br Rd, London SE1
31	7EH, UK, <u>tim.spector@kcl.ac.uk</u>

32

33	Metabolic responses to food influence cardiometabolic disease risk, but large-scale high-resolution
34	studies are lacking. We recruited n=1,002 twins and unrelated healthy adults in the UK into the
35	PREDICT1 study and assessed postprandial metabolic responses in a clinic setting and at home. We
36	observed large inter-individual variability (population coefficient of variation [SD/mean]%) in
37	postprandial blood triglyceride (103%), glucose (68%), and insulin (59%) responses to identical
38	meals. Person-specific factors, such as the gut microbiome, had a greater influence (7.1% of
39	variance) than meal macronutrients (3.6%) for postprandial lipemia, but not for postprandial
40	glycemia (6.0% and 15.4% respectively); genetic variants had a modest impact on predictions (9.5%
40 41	glycemia (6.0% and 15.4% respectively); genetic variants had a modest impact on predictions (9.5% for glucose, 0.8% for triglyceride, 0.2% for c-peptide). Findings were independently validated in a US
41	for glucose, 0.8% for triglyceride, 0.2% for c-peptide). Findings were independently validated in a US

45

46 Introduction

47 Effective prevention strategies are required to reduce the immense global burden of nutrition-48 related non-communicable diseases (NCD)¹. Nutritional research and the corresponding guidelines²⁻⁴ focus on population averages. However, the high between-person variability in response to foods 49 50 and weight-loss diets⁵ demands development of more personalized approaches. Empirically-based 51 precision nutrition requires research using multi-dimensional, high-resolution time-series data from 52 adequately powered studies⁶. The application of technologies to accurately and precisely quantify 53 many postprandial (non-fasting) traits in large cohorts and in real-world settings is extending 54 capabilities in this field of research.

55

Although fasting blood assays are used in many clinical diagnoses, most people are predominantly in
 the postprandial state during waking hours. Postprandial lipid, glucose and insulin dyshomeostasis

are independent risk factors for NCDs and obesity^{7,8,9}. Postprandial hyperglycemia raises risk of cardiovascular disease (CVD), coronary heart disease (CHD) ¹⁰ and cardiovascular mortality, even in individuals with normal fasting glucose¹¹, and postprandial triglyceride is more predictive of CVD than fasting concentrations ^{12,13}, highlighting the relevance of diet and its metabolic consequences in cardiovascular risk.

63

64 A person's unique postprandial glycemic and lipiaemic responses are likely attributable their biological (e.g. microbiome and nuclear DNA variation) and lifestyle characteristics^{2,14}, as 65 66 demonstrated previously for specific meals⁵. While postprandial glycemic responses are important 67 health determinants, glycemic control is just one part of a more complex metabolic equation 68 involving triglyceride (the primary alternative energy substrate to glucose) and insulin (regulating 69 glucose and triglyceride transport and metabolism)¹⁵. Thus, also characterizing postprandial 70 regulation of lipids and identifying the factors responsible for individual variations could help 71 optimize diet recommendations targeting broader improvements in cardiometabolic health. 72 73 The PREDICT 1 clinical trial (NCT03479866) was designed to quantify and predict individual variations 74 in postprandial triglyceride, glucose and insulin responses to standardized meals. PREDICT 1 enrolled 75 twins and unrelated adults from the UK in whom genetic, metabolic, microbiome composition, meal 76 composition and meal context data were obtained to distinguish predictors of individual responses 77 to meals. These predictions were validated in an independent cohort of adults from the USA. 78 79 Our findings show wide variations in postprandial responses between people, even identical twins, 80 attributable in large part to modifiable factors. We found that people who experience poor 81 metabolic responses to a given meal are likely to respond poorly to other meals of the same 82 macronutrient profile, and the overall correlation between postprandial glucose and triglyceride

responses is weak. The postprandial prediction models we have developed could help to optimize
personalized diet recommendations.

85

86 Results:

87

88	1002 healthy adults from the UK completed baseline clinic measurements consisting of postprandial
89	metabolic responses (0-6h; blood triglyceride, glucose and insulin concentrations) to sequential
90	mixed-nutrient dietary challenges. Findings were validated a US cohort of 100 healthy adults.
91	Additional data was collected over the subsequent 13-day period at home, where postprandial
92	responses to eight meals (seven in duplicate) of different macronutrient (fat, carbohydrate, protein
93	and fiber) content were measured using continuous glucose monitors (CGM) and dried blood spot
94	(DBS) analysis. The study design is described in detail in the Methods and Figure 1, the inclusion
95	criteria and descriptive characteristics of study subjects are presented in Supplemental Table 1.
96	Further information on the research design is available in the Life Sciences Reporting Summary
97	linked to this article.
98	

99 Inter- and intra-individual variation in postprandial responses

100 Inter-individual variability in postprandial responses was examined in a tightly controlled clinic 101 setting following the sequential standardized test meal challenge after fasting (Figure 2a). The inter-102 individual patterns of response for each outcome was assessed using Levene's test of variance. 103 Heterogeneity across all postprandial time-points (fasting to 6-hrs) varied greatly for triglyceride 104 (p=3.931e-11), glucose (p=2.91e-194) and insulin (p=2.45e-17) concentrations. In serum, the 105 population coefficient of variation was higher for postprandial triglyceride_{6hr-rise} (103%) and 106 glucose_{iAUC0-2h} (68%) compared with fasting values (50% and 10%, respectively). This was not true for 107 insulin_{iAUC0-2h} (59%) compared to fasting (69%; Figure 2a), suggesting that these measures of

postprandial triglyceride and glucose concentrations, but not insulin, provide better discriminationof an individual's metabolic tolerance than fasting values.

110

A key assumption when developing personalized prediction algorithms is that an individual's unique
 response to the same meal is reproducible. Much of the between-person phenotypic variability
 observed in studies examining response to diet interventions that include only a single test–

114 response scenario could be a result of regression to the mean and other sources of error. Repeated-115 measures (multiple measures taken within individual at a single time-point and across multiple time 116 points) can be used to partition error from true biological variability, thereby improving the precision 117 of the estimate. Accordingly, we administered test meals of varying macronutrient composition in 118 duplicate per participant, under similar conditions (see Methods and Supplemental Table 2 for 119 details). We also used continual glucose monitors (CGMs), which provided sequential measures of 120 blood glucose at 5 minute intervals during the study period. Intra-individual variability (repeatability) 121 was assessed using intra-class correlation coefficients (ICC) for triglyceride, C-peptide (from DBS assays) and glucose (from CGM) measurements. The ICCs were: triglyceride ender =0.46 [95% CI 0.37, 122 123 0.54]; glucose, uccan = 0.74 [95% CI 0.72, 0.75]; C-peptide, e= 0.62 [95% CI 0.54, 0.69] (Supplemental 124 Table 3). The differences in ICCs between triglyceride, C-peptide and glucose measurements partly 125 reflect the different assays used (DBS and CGM) (see Methods).

126

127 Predicting individual postprandial responses within a population

We assessed the overall extent to which input variables (**Supplemental Table 3**) predict personal postprandial responses (**Figure 2b-d**), initially using multivariable linear regression. Input variables include: i) baseline characteristics (age, sex, clinical biochemistry (lipid, glycaemic and other measures), anthropometry)); ii) genetics (single nucleotide polymorphisms (SNPs)); iii) gut microbiome features); iv) habitual diet (from Food Frequency Questionnaire (FFQ)); v) meal context

- 133 (sleep, previous meals, physical activity, meal sequence and /or timing); vi) meal composition
 - 5

134 (energy from carbohydrate, sugar, fat, protein and fiber). Postprandial glycemic responses were 135 determined from serum and CGM measurements in the clinic and at home (from 7 standardized 136 meals and 6,616 readings; see Methods). Postprandial C-peptide and triglyceride were determined 137 (from two standardized meals) from serum and DBS assays collected during the clinic and home 138 phases . We also tested the correlation between fasting and postprandial characteristics and found 139 that the correlation between postprandial triglyceride, with regards to postprandial glucose and 140 postprandial C-peptide measures was low (Figure 3a).

141 Individual baseline characteristics. The proportions of trait variance explained by individual baseline 142 characteristics are shown in Figures 2b, c and d for triglyceride 6h-rise, glucoseiAUC0-2h, and C-peptide1h-

143 rise respectively (Supplemental Table 3).

(Supplemental Table 4).

144 Genetic factors . The heritability of postprandial responses in the UK cohort was examined using 145 classical twin methods (variance components analyses) to establish the upper bound of what might 146 be predicted by directly measured genetic variation. Two-thirds of the cohort was recruited from the TwinsUK registry ¹⁶, of which 230 twin pairs (n=460; 183 MZ and 47 DZ) were studied for heritability. 147 148 Additive genetic factors explained 30% of the variance in glucose_{iAUC0-2h}, whereas only 4% of the 149 variance in triglyceride6h-rise and 9% of the variance in insulin2h-rise were explained in this way 150 (Figure 3b). The estimated genetic variances in insulin_{1h-rise} and C-peptide_{1h-rise} were close to zero 151

152 SNP-based genetic factors. In a subgroup of participants who are part of the TwinsUK cohort and 153 had genome wide genotyping previously measured with available GWAS data (n=241), we tested 154 whether 32 SNPs derived from previous genome-wide scans of postprandial glucose, insulin or triglyceride concentrations ¹⁷⁻²¹ were also associated with the postprandial variables studied here. 155 156 Several SNPs were significantly (p<0.05) associated with these variables (Figure 3c and 157 Supplemental Table 4), but collectively explained only ~9% of observed variation in glucoseiAUCO-2h (Figure 2c), and less than 1% of variation for postprandial triglyceride and postprandial C-peptide
(Figure 2b and 2d).

160 Gut microbiome (16S rRNA). We estimated the contribution of gut microbiome composition using 161 relative bacterial taxonomic abundances and measures of community diversity and richness, derived 162 from 16S rRNA high-throughput sequencing of baseline stool specimens (Supplemental Table 4). We 163 found that without adjusting for any other individual characteristics the gut microbiome 164 composition explained 7.5% of postprandial triglyceride_{6h-rise}, 6.4% of postprandial glucose_{iAUCO-2h} and 165 5.8% of postprandial C-peptide1h-rise. 166 *Meal composition, habitual diet and meal context.* To determine the impact of the macronutrient 167 composition of meals, we measured triglyceride_{6h-rise} and C-peptide_{1h-rise} for two standardized home 168 phase meals of contrasting macronutrient compositions (for triglyceride, comparison of meals 1 and 169 7: 85 vs 28g of carbohydrate and 50 vs 40 g of fat at breakfast, both followed by a lunch of 71g 170 carbohydrate and 22g fat; for C-peptide, comparison of meal 2 and 3: 71 vs 41 g of carbohydrate and 171 22 vs 35 g of fat; **Supplement Table 2**) in subsets of participants (n=712 and n=186, 172 respectively). Glucose_{iAUC0-2h} was measured for seven standardized meals (comparison of meals 1, 2, 173 4, 5, 6, 7 and 8: 28 - 95 g carbohydrate; 0 - 53 g fat) totalling 9,102 meals in 920 individuals. The 174 proportions of variance explained by meal composition, habitual diet, and by meal context are

shown for triglyceride_{6h-rise}in Figure 2b, for glucose_{iAUC0-2h}in Figure 2c, and for C-peptide_{1h-rise}in Figure
2d. A multivariate regression model (meals 1, 2, 4, 5, 6, 7 and 8) revealed that the Glucose_{auco-2h}
(mmol/L*s) was significantly (P<0.001) reduced by 79, 142 and 185 for every 1g fat, fiber and protein
respectively, after adjustment for carbohydrate consumption.

179

180 Machine learning model. To estimate the unbiased predictive utility of the factors analysed, we
181 used a machine learning approach robust to overfitting²². Random Forest regression models²³ were
182 fitted using all the informative features (meal composition, habitual diet, meal context,

183 anthropometry, genetics, microbiome, clinical and biochemical parameters) to predict triglyceride 5h-

rise, glucoseiAUCO-2h and C-peptide1h-rise in the UK cohort dataset. The predicted values were compared
with the observed values for each trait using Pearson correlation coefficients (r); these correlations
were r=0.47, r=0.77 and r=0.30 for triglyceride6h-rise, glucoseiAUCO-2h and C-peptide1h-rise, respectively.
Similar correlations were observed in the held-out validation set (US cohort) and the model predictions
for triglyceride6h-rise and glucoseiAUCO-2h were r=0.42 and r=0.75, respectively, but much weaker for Cpeptide1h-rise (r=0.14) (Figure 4). The features used to fit the models are reported in Supplemental
Table 5. The repeatability and robustness of the machine-learning model is presented in the

191 Extended Data Figure 4.

192 Postprandial responses in relation to surrogate scores of clinical outcomes. We compared the

193 extent to which fasting and postprandial concentrations for the different biomarkers could be used 194 to predict impaired glucose tolerance (7.8-11.0 mmol/L 2 hours after an OGTT) and atherosclerotic 195 cardiovascular disease (ASCVD) 10-yr risk score (Methods) by comparing the area under the receiver 196 operator characteristics (ROC-AUC) curves; Figure 5. We found that fasting triglyceride and 197 triglyceride_{6h-rise} contributed similarly to the ROC-AUC for ASCVD risk, and that including both was 198 more informative than including only one of them (Figure 5a). We also found that, although 199 postprandial glucose was not as informative as fasting glucose, adding glucoseiAuco-2h to fasting 200 glucose resulted in a slightly higher ROC-AUCs (0.72 vs 0.69) for ASCVD 10-yr risk. Fasting C-peptide 201 and fasting glucose were as effective (ROC AUC= 0.69) as fasting triglyceride in ASCVD prediction, 202 whereas postprandial C-peptide (ROC AUC= =0.63) and postprandial glucose were weaker (ROC 203 AUC= 0.62) than postprandial triglyceride (ROC AUC= 0.71). Fasting and postprandial triglyceride 204 concentrations were weakly predictive (ROC AUC= 0.55 and 0.59, respectively) of impaired glucose 205 tolerance (IGT), whereas fasting and postprandial C-peptide were moderately predictive (ROCAUC= 206 0.64 and 0.65 respectively), although with no added predictive value in combination. We did not 207 include here the prediction of IGT using CGM glucose. This is because IGT is defined solely based on 208 the blood glucose concentration at 2hrs during an OGTT, which is captured by the CGM glucose

209 recording, and so the derivation of the predictor and the clinical score variables would be heavily

210 dependent upon one another. Results were similar in the UK and US cohorts (Figure 5).

211

212 Decoding individual responses

Having investigated postprandial responses within the population, we then explored the responses at the individual level. We examined glycemic responses, as the granular CGM data collected during the at-home phase enabled us to assess real-world effects in detail, which was not possible for triglyceride or C-peptide. We investigated how much of an individual's postprandial response is a attributable to a meal's glycemic properties, compared with how the variation resulting from other modifiable factors such as meal timing, exercise and sleep.

219 We first examined the contribution of the meal. Although it is a widely held notion that, for an 220 individual, variations in meal composition are primarily responsible for the variation in responses to 221 food and that ranking of meal responses should be the same for all people²⁴⁻²⁵, we explored whether 222 meal-specific responses unique to the individual exists. We ranked the order of each participant's glucose for every possible pair of standardized meals consumed at home. We then determined 223 224 how frequently these rankings differed for each participant. For most pairs of meals, the ranking was 225 the same for all individuals (e.g. OGTT has a higher glucose_{iAUC0-2h} than high-fiber muffins in all 226 participants, Figure 6a). However, for select pairs of meals, the ranking was reversed in up to 48% of 227 participants, such as between the medium fat and carbohydrate at lunch vs high carbohydrate 228 breakfast (350 of 727 participants) (meal 2 vs. meal 4; Supplemental Table 2). In 186 out of 498 229 (37.3%) participants, discrepancies were also seen between the high fat and the high protein meals (meals 7 and 8). The distribution of how these meals were ranked for the participants of the 230 231 PREDICT study is presented in Extended Data 2.

We note that the reordering of meal rankings could have been the result of noise. We therefore
used ANOVA to estimate the effect size for the different factors explaining glycemic response (Figure
6b), including person-specific effects (effects that vary between people but not between meals). As

described in the Methods, we considered not only the effect of the meal macronutrient and energy
content in the response (meal composition), but also considered how each individual responded on
average to all their set meals relative to the population (individual glucose scaling), as well as the
effect of the individual's meal-specific response, the error attributable to the glucose measurement
and other sources of variation (including modifiable sources of variation such as sleep, circadian
rhythm and exercise).

We found that, consistent with the linear models described earlier, the ANOVA models show that there are three meal-related factors explaining individual glycemic responses. Meal macronutrient composition alters iAUC by 16.73% (95%Cl 15.37 - 18.92%), but the individual glucose scaling is larger, altering iAUC by roughly 18.74% (17.96% - 19.46%), while the individual's meal-specific response is much smaller, affecting the final meal iAUC by 7.63% (6.11% - 8.96%). Other modifiable sources of variation not directly related to the meal composition, such as meal timing, exercise and sleep, contributed similar amounts of variance as the meal's composition (**Figures 6b and c**).

To investigate whether modifying the order in which meals are consumed and time of the day affect glycemic responses, we looked at participants eating an identical meal (meal 2) for breakfast and lunch. The average glycemic response for the same individuals was on average 2-fold higher (tstatistic = -35.7, 2721 d.f.; P< 0.001) when the meal was ingested for lunch (mean glucose 2h iAUC=14254 SD=6593) (4h following the metabolic challenge breakfast) than when ingested for breakfast (mean glucose 2h iAUC=7216, SD=4157), although with wide individual variation (**Figure**

254 **6c**).

255 Discussion:

Nutrition and health are intimately linked. Each day people make diet-related decisions that are influenced by perceived enjoyment and satiation, as well as health benefits and harm attributed to specific foods and beverages. Standard nutritional guidelines ²⁻⁴ are typically based on population averages. However, it is increasingly evident that one-size nutritional recommendations do not fit all, which is exemplified by the variable efficacy of tightly controlled lifestyle intervention trials²⁶⁻²⁹. To address these challenges, we undertook a two-week interventional trial, including a tightlycontrolled in-clinic day and a two-week at-home phase, where postprandial metabolic responses to a series of standardized meals were obtained in more than 1,000 healthy adults from the UK and USA. The primary aim was to derive algorithms that predict an individual's postprandial metabolic responses to specific foods. The core outcomes were variations in blood concentrations of triglyceride, glucose and insulin (or C-peptide), as these biomarkers work in concert to affect cardiometabolic risk^{8,30}.

In many cases, we observed responses that contrast with those reported in traditional clinic-based studies, thereby reshaping conclusions about the key factors influencing responses to foods. For example, genetic influence was less than expected, especially for triglyceride, while modifiable factors like meal timing conveyed larger effects than anticipated.

272 Meal composition has large effects on postprandial insulinemic and lipidemic response³¹Some small 273 studies suggest that meals with high-fat and/or protein content elicit very different postprandial 274 responses than lower-fat and/or protein meals with identical carbohydrate content (reviewed in ³¹). 275 The type of fat in a meal also alters the lipemic response³². However, measuring postprandial 276 triglyceride and C-peptide at-home in large cohorts is both logistically challenging and places a 277 considerable burden on. Thus, for pragmatic reasons, only two pairs of meals (high fat and high 278 carbohydrate, respectively) were used to calculate postprandial triglyceride and C-peptide responses 279 and the difference in macronutrient content of these meals was low. This limited number of 280 different meals and their relatively similar macronutrient content might explain why the effects 281 seen for postprandial triglyceride and C-peptide were lower than expected.

282 In addition to fasting concentrations of triglyceride and glucose, we found that postprandial

triglyceride and glucose concentrations were informative for IGT and CVD risk determination.

284 However, postprandial C-peptide measurements provided no additional information over fasting

concentrations. We found that although postprandial triglyceride and glucose responses were highly
variable between individuals, a person's response to the same meals was often similar and therefore
predictable. Any given individual generally responds comparably to different meals of the same
macronutrient profile, with some people experiencing large postprandial excursions across most
meals, whereas others consistently experience modest responses. This is important for
individualized prediction and recommendations, as it suggests that once one has learned about an
individual's postprandial response to specific foods, their response to other foods could be inferred.

292 We show that a person's glycemic response is the result not only of individual-specific glucose 293 scaling, which determines whether a person is a high or low responder to all meals, but that there 294 are also meal-specific responses unique to an individual. Possible explanations include individual 295 genetic differences in the ability to digest high-starch meals³³. Zeevi and co-workers⁵ reported an 296 example where one participant had an exaggerated glycemic response to a banana but not to a 297 cookie, whereas the second participant had the opposite response. We assessed this phenomenon 298 in our data and found that individual glucose scaling and meal-specific responses both exist, but 299 individual meal-specific responses are generally much more effective than scaling.

300 People differ greatly in their responses to diet interventions. The DIETFITS study, for example, 301 randomised 609 people to either a healthy low fat or a healthy low carbohydrate diet for 12-302 months³⁴. By study end, average weight loss was similar between groups (~5-6kg), but wide 303 variations were seen within groups (-30kg to +10kg). Elsewhere, the Diabetes Prevention Program 304 showed that although a standardized intensive lifestyle intervention focusing on changes in diet 305 (tailored only to the energy requirements of the individual) lowered diabetes risk substantially²⁸, its 306 efficacy varied greatly across the study population ^{26,27}, and was determined to some extent by genetic factors²⁹. While response to diet interventions will depend partly on adherence, findings 307 308 from the PREDICT trial and elsewhere^{35,36} suggest that even in highly-adherent participants,

substantial response variations exist, which might be predictable. In PREDICT, non-food-specific
 factors (e.g., meal timing, sleep, activity) were highly informative of these person-specific responses.

318 The prediction algorithms we developed are likely to have been strengthened by the use of

319 randomized, mixed meals, containing combinations of macronutrients reflective of those seen in 320 real-world settings, rather than supra-physiological lipid or carbohydrate challenges, as used in 321 previous studies.

322 In general, genetics, contrary to our expectations, was not a predominant determinant of these 323 responses; we found that the heritable fraction (the trait variance explained by additive genetic 324 factors) of C-peptide and/or insulin concentrations at 1 hr was very low (0.3%) and at 2 hrs remained 325 low (9.1%). The heritable fractions for postprandial triglyceride (6hr rise) and glucose (2hr iAUC) 326 responses were higher, but still modest (16% and 30%, respectively). Despite the wealth of publicly 327 available SNP data (see: www.type2diabetesgenetics.org), there is no robust data for these specific 328 postprandial traits, as almost all published GWAS of serological traits have focused on fasting values. 329 Nevertheless, in exploratory analyses, we examined the predictive value of loci previously linked to 330 post-challenge triglyceride, glucose or insulin concentrations ¹⁷⁻²¹ but found that the predictive utility 331 of these variants was poor, particularly for triglyceride and C-peptide (Figure 3c). The modest 332 heritability of postprandial traits means that even in an unrealistically optimistic scenario, where

most of this trait variance is explained by known DNA variants, it is unlikely that prediction

algorithms using DNA variant data alone, which many direct-to-consumer nutrigenomics companies
 advocate, would succeed.

336 The lack of a major genetic component to these traits highlights the likely involvement of modifiable 337 environment exposures. Indeed, we found that meal composition and context (e.g. meal timing, 338 exercise, sleep and circadian rhythm) were core determinants of postprandial metabolism. These 339 predictions were strengthened using data on gut microbiome diversity. Using machine learning 340 combining all relevant data, an individual's postprandial triglyceride and glycemic responses could 341 be meaningfully predicted, with similar results in the US validation cohort. For C-peptide, the 342 prediction was much weaker in the validation cohort (r=0.30 UK, r=0.14 US), possibly reflecting the 343 lower number of test meals relative to the number of input variables, which could adversely affect 344 the reliability of the prediction³⁷. The postprandial glycemic predictions were similar to those 345 reported by Zeevi and colleagues⁵, although the analysis methods and input features are not directly 346 comparable.

347 Despite having developed these prediction algorithms, there is scope for improvement, such as 348 inclusion of a more diverse array of meal interventions and with more detailed assessments of 349 contextual factors than in the current study. Technological advances could also help to improve 350 predictions. For example, although glucose can be continuously assessed with CGMs, no 351 commercially available devices suitable for free-living assessments of continuous insulin and 352 triglyceride concentrations currently exist. Moreover, owing to the differences in tolerability and the lower limit of detectable responses of dietary carbohydrates compared with fats ³⁸, our trial suggests 353 354 that the prediction of postprandial glucose is methodologically superior to triglyceride responses 355 (see Fig 2b-d). Difficulties in directly comparing changes in triglyceride and glucose were a limitation 356 of our study. Continuous, accurate measures of these traits could substantially improve predictions 357 owing to reductions in model error and the ability to study non-linear patterns of response, which

358 may be important. The inclusion of deep '-omics' data may further enhance the predictive ability of 359 these algorithms; for example, here we used microbiome data derived from 16S RNA sequencing, 360 which, whilst proving valuable for prediction (explaining 6.4% and 7.5% of the variances for glucose 361 and triglyceride responses, respectively), may prove even more informative if derived from higher-362 resolution metagenomic sequencing. The nutritional signatures detectable within the metabolome, both in blood³⁹ and feces ⁴⁰, suggest that including a larger metabolomics panel and quite probably 363 364 other -omics data, e.g. meta-transcriptomics, transcriptomics or proteomics, in our algorithms would 365 add costs but also enhance predictions. Using FFQs, we found that habitual diet explains a small 366 proportion (<2%) of an individual's postprandial responses. However, FFQs have well-known 367 limitations, and other objective approaches may be considerably less biased and error prone²⁷. 368 Pairing this with short-term assessments, like the weighed dietary record included in the PREDICT 369 study app, may help mitigate these limitations. More comprehensive challenge tests might also 370 reveal new aspects of postprandial metabolism; here, we used a 6-hr meal tolerance test, as this was 371 deemed the maximum duration that most participants were likely to accept. Data from longer 372 duration challenge tests (up to 8hrs), for both glucose and triglyceride responses, may provide 373 valuable information.

For postprandial triglyceride and glucose responses, the prediction models derived in the UK cohort
performed almost as well in the independent US validation cohort, which is reassuring given
differences in environmental factors; nevertheless, both cohorts were comprised of younger healthy
adults of European ancestry. Thus, the generalization of our findings would require validation in
people of non-European ancestry, older adults, and in people with diseases that affect metabolism
such as diabetes. The clinical implications of our predictions will require appropriately powered
longitudinal studies.

In conclusion, this is the most comprehensive assessment to date of metabolic responses to
 nutritional challenges in a rigorous intervention setting. We observed considerable inter-individual

- 383 differences in postprandial metabolic responses to the same meals, challenging the logic of
- 384 standardized diet recommendations. These findings, in addition to the scalability of the assessment
- 385 methods and the accuracy of the prediction algorithms described here, mean that, at least from a
- 386 cardiometabolic health perspective, population-wide personalized nutrition has potential as a
- 387 strategy for disease prevention.

388

389 Author contributions

- 390 Obtained funding: J.W., G.H., T.D.S.. Study design and developed concept: S.E.B., A.M.V., J.W., G.H.,
- 391 R.D., A.T.C., N.S., P.W., P.W.F., T.D.S.. Data collection: S.E.B., D.A.D., H.A.K., M.Mangino, J.M., .IL.,
- 392 D.H.. Data analysis: A.M.V., M.Mangino., F.A., R.D., J.C., C.B., S.G., E.B., M.Mazidi, P.W., N.S.. Study
- 393 coordination: S.E.B., H.A.K., D.A.D., G.H., J.W.. Writing the manuscript S.E.B., A.M.V., D.A.D.,
- M.Mazidi, J.W., J.C., I.L., J.M.O., C.D.G., L.M.D., A.T.C., N.S., P.W.F. and T.D.S.. All authors reviewed
 and revised the final manuscript.
- 396

397 Acknowledgements

398	We express our sincere thanks to the participants of the PREDICT 1 study. We thank Mark McCarthy
399	(University of Oxford) and Leanne Hodson (University of Oxford) for valuable feedback on the
400	manuscript. We thank the staff of Zoe Global, the Department of Twin Research and Massachusetts
401	General Hospital for their tireless work in contributing to the running of the study and data
402	collection. We thank Abbott for their support with using their CGMs. This work was supported by
403	Zoe Global Ltd also received support from grants from the Wellcome Trust (212904/Z/18/Z) and the
404	Medical Research Council (MRC)/British Heart Foundation Ancestry and Biological Informative
405	Markers for Stratification of Hypertension (AIMHY; MR/M016560/1). PWF was supported in part by
406	grants from the European Research Council (CoG-2015_681742_NASCENT), Swedish Research
407	Council, Novo Nordisk Foundation and the Swedish Foundation for Strategic Research (IRC award).

408 AMV was supported by the National Institute for Health Research Nottingham Biomedical Research 409 Centre. TwinsUK is funded by the Wellcome Trust, Medical Research Council, European Union, 410 Chronic Disease Research Foundation (CDRF), Zoe Global Ltd and the National Institute for Health 411 Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre 412 based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. 413 414 Conflict of interest statement: TD Spector, SE Berry, AM Valdes, F Asnicar, PW Franks, LM 415 Delahanty, N Segata, are consultants to Zoe Global Ltd ("Zoe"). J Wolf, G Hadjigeorgiou, R Davies, H 416 Al Khatib, J Capdevila, C Bonnett, S Ganesh, E Bakker, P Wyatt and I Linenberg are or have been 417 employees of Zoe. Other authors have no conflict of interest to declare. 418 419 Data availability 420 The data used for analyzing this study are held by the department of Twin Research at Kings College 421 London. The data can be released to bona fide researchers using our normal procedures overseen by 422 the Wellcome Trust and its guidelines as part of our core funding. We receive around 100 requests 423 per year for our datasets and have a meeting three times a month with independent members to 424 assess proposals. Application is via https://twinsuk.ac.uk/resources-for-researchers/access-our-425 data/. This means that the data needs to be anonymized and conform to GDPR standards. 426 Specifically for this paper, all the variables used in the models can be requested as well as the 427 summary outcome measures for each person. The 16S microbiome data used here will be uploaded 428 onto the EBI website (<u>https://www.ebi.ac.uk/</u> with unlimited access. 429 430 Code availability

431 The scripts for statistical analysis are freely available upon request to the Department of Twins

432 Research. Application is via https://twinsuk.ac.uk/resources-for-researchers/access-our-data/.

433

434 Figure Legends

435

- 436 Figure 1. Experimental design. The PREDICT 1 study comprised a primary UK-based cohort
- 437 (*n_{max}=1,002*) and an independent US-based validation cohort (*n_{max}=100*).

438

439 Figure 2. Variation in postprandial responses. a. Inter-individual variation in trialyceride, glucose 440 and insulin postprandial responses to the breakfast and lunch meal challenges in the clinic (n=1002). 441 b. Determinants of triglyceride 6h-rise measured from DBS (comparison of meals 1 and 7). c. 442 Determinants of glucoseiAUCO-2h measured by CGM (comparison of 7 test meals; 1, 2, 4, 5, 6, 7 and 8). 443 d. Determinants of C-peptide 1h-rise measured from DBS as a proxy for insulin (comparison of meals 2 444 and 3). Trait variations explained for each input variable are derived from separate (non-hierarchical) 445 regression models. Values represent adjusted- R^2 and error bars reflect 95% confidence intervals. 446 Meal composition and Meal context adjusted- R^2 values were derived from meal sample sizes as 447 follows; triglyceride6h-rise, n=712; glucoseiAUC0-2h, n=9102; C-peptide1h-rise, n=186. All other determinant 448 values were derived from meal sample sizes as follows; triglyceride_{6h-rise}, n=920; glucose_{iAUC0-2h}, 449 n=958; C-peptide_{1h-rise}, n=960. TG= triglyceride, DBS= dried blood spots, CGM= continuous glucose monitor. * p<0.05, ** p<0.01, *** p<0.001 using multivariable linear regression. 450

451

- 452 Figure 3. Relationship of baseline values, genetic and microbiome factors to postprandial
- 453 responses. a. Pearson correlations between baseline values and postprandial prediction measures of
- 454 980 participants from the UK cohort. b. Heritability of postprandial responses (the ACE model was
- 455 fitted on log-scaled postprandial responses for triglyceride, glucose, insulin and C-peptide) in 183 MZ
- 456 and 47 DZ twin pairs. A; additive genetic component, C; shared environmental component, E;
- 457 individual environmental component. c. SNP associations with postprandial measures focusing on
- 458 SNPs identified in published postprandial trait GWAS¹⁷⁻²¹ (n=241; * p<0.05, *** p<0.001, using two-
- 459 sided chi-squared test).

461	Figure 4 - M	lachine learning	models fitted i	in to postprandial	measures. a.	Machine learning model

- 462 for TG_{6h-rise} in the UK cohort. **b**. Machine learning model for glucose_{iAUC0-2h} in the UK cohort. **c**.
- 463 Machine learning model for C-peptide1h-rise postprandial responses in the UK cohort. The machine

learning models in the US validation cohort are shown in Figures 4 d-f. The relationship between
variables is expressed as Pearson's correlation coefficient (r) and denoted with a regression line; n
represents participant number; the features used to predict each value are the same as those listed in
the linear models in Figure 2b-d.

468 Figure 5. Associations between fasting and postprandial values for TG, C-peptide and glucose 469 concentrations with clinical measures in the UK cohort. Receiver operator characteristics curves 470 illustrating the predictive utility of fasting and postprandial TG, glucose and C-peptide measures to 471 discriminate the bottom 70% from the top 30% of the cohort (cut-off ASCVD 10 year risk of 0.0183) 472 for **a**. atherosclerotic cardiovascular disease (ASCVD) 10-year risk n=951 independent samples from 473 the UK and **b**. impaired glucose tolerance (IGT) n= 826 independent samples from the UK. The same 474 analyses were performed in the US cohort (n=92 independent samples) resulting in ROC AUC (95%CI) 475 values for ASCVD 10 year risk of: C-peptide fasting AUC=0.68 (0.56-0.80), postprandial AUC=0.66 476 (0.54-0.77), both AUC=0.69 (0.58-0.81); **TG** fasting AUC=0.73(0.63-0.84), postprandial AUC=0.75 477 (0.65-0.85), both AUC = 0.77 (0.67-0.88); and glucose fasting AUC= 0.74-(0.63-0.85), postprandial 478 AUC = 0.64 (0.52-0.76), both AUC = 0.76 (0.64-0.85). For impaired glucose tolerance values were: C-479 peptide fasting AUC = 0.66 (0.53-0.80), postprandial AUC = 0.59 (0.46-0.72), both AUC = 0.67 (0.54-480 0.80); and Triglyceride fasting AUC = 0.66 (0.53-0.80), postprandial AUC = 0.59 (0.46-0.72), both 481 AUC = 0.61 (0.54-0.80).

Figure 6. Person-specific diversity in postprandial response. a. Proportion of times in the PREDICT 1
study that the ranking of the glycemic response (glucose_{iAUC0-2h}) to pairs of set meals was altered
(n=828, UK cohort). *b.* Effect size for factors explaining glycemic response. The different sources of
variation were estimated using ANOVA, as described in Supplemental Table 3. The x-axis can be
approximately interpreted as percent increase (or decrease) in iAUC attributable to the model
parameters (n=483 individuals) *c.* Time of day effects. (n=920, UK cohort). Boxes show quartiles (25th,
50th, 75th percentiles); whiskers show the 95% interval.

491	
492	

493 **References**

- 494
- 495 1. Collaborators, G.B.D.D. Health effects of dietary risks in 195 countries, 1990-2017: a 496 systematic analysis for the Global Burden of Disease Study 2017. Lancet **393**, 1958-1972 497 (2019). 498 Agriculture, U.S.D.o.H.a.H.S.a.U.S.D.o. 2015 - 2020 Dietary Guidelines for Americans. 8th 2. 499 Edition. December 2015. Available at https://health.gov/our-work/food-and-500 nutrition/2015-2020-dietary-guidelines/.(2015). 501 3. Karpyn, A. Food and public health : a practical introduction, xv, 368 pages (Oxford University 502 Press, New York, 2018). 503 4. (EFSA), E.F.S.A. Dietary Reference Values for nutrients Summary report. 504 https://doi.org/10.2903/sp.efsa.2017.e15121(2017). 505 Zeevi, D. et al. Personalized Nutrition by Prediction of Glycemic Responses. Cell 163, 1079-5. 506 1094 (2015). 507 6. Tebani, A. & Bekri, S. Paving the Way to Precision Nutrition Through Metabolomics. Front 508 Nutr 6, 41 (2019). 509 7. Kolovou, G.D. et al. Assessment and clinical relevance of non-fasting and postprandial 510 triglycerides: an expert panel statement. Curr Vasc Pharmacol 9, 258-70 (2011). 511 8. Astley, C.M. et al. Genetic Evidence That Carbohydrate-Stimulated Insulin Secretion Leads to 512 Obesity. Clin Chem 64, 192-200 (2018). 513 9. Blaak, E.E. et al. Impact of postprandial glycaemia on health and prevention of disease. Obes 514 Rev 13, 923-84 (2012). 515 10. Decode Study Group, t.E.D.E.G. Glucose tolerance and cardiovascular mortality: comparison 516 of fasting and 2-hour diagnostic criteria. Arch Intern Med 161, 397-405 (2001). 517 11. Ning, F. et al. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h 518 plasma glucose levels within a normoglycemic range. *Diabetes Care* **33**, 2211-6 (2010). 519 12. Bansal, S. et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular 520 events in women. JAMA 298, 309-16 (2007). 521 13. Lindman, A.S., Veierod, M.B., Tverdal, A., Pedersen, J.I. & Selmer, R. Nonfasting triglycerides 522 and risk of cardiovascular death in men and women from the Norwegian Counties Study. Eur 523 J Epidemiol 25, 789-98 (2010). 524 14. Jackson, K.G., Poppitt, S.D. & Minihane, A.M. Postprandial lipemia and cardiovascular 525 disease risk: Interrelationships between dietary, physiological and genetic determinants. 526 Atherosclerosis 220, 22-33 (2012). 527 15. Stumvoll, M., Goldstein, B.J. & van Haeften, T.W. Type 2 diabetes: principles of pathogenesis 528 and therapy. Lancet 365, 1333-46 (2005). 529 16. Moayyeri, A., Hammond, C.J., Hart, D.J. & Spector, T.D. The UK Adult Twin Registry (TwinsUK 530 Resource). Twin Res Hum Genet 16, 144-9 (2013). 531 17. Prokopenko, I. et al. A central role for GRB10 in regulation of islet function in man. PLoS 532 Genet 10, e1004235 (2014). 533 18. Saxena, R. et al. Genetic variation in GIPR influences the glucose and insulin responses to an 534 oral glucose challenge. Nat Genet 42, 142-8 (2010). 535 19. Wojczynski, M.K. et al. Genome-wide association study of triglyceride response to a high-fat 536 meal among participants of the NHLBI Genetics of Lipid Lowering Drugs and Diet Network 537 (GOLDN). Metabolism 64, 1359-71 (2015). 538 20. Sanna, S. et al. Causal relationships among the gut microbiome, short-chain fatty acids and 539 metabolic diseases. Nat Genet 51, 600-605 (2019).

540	21.	Almgren, P. et al. Genetic determinants of circulating GIP and GLP-1 concentrations. JCI
541		Insight 2 (2017).
542	22.	Wojcikowski, M., Ballester, P.J. & Siedlecki, P. Performance of machine-learning scoring
543		functions in structure-based virtual screening. Sci Rep 7, 46710 (2017).
544	23.	Hastie, T., Tibshirani, R. & Friedman, J. The Elements of Statistical Learning: Data Mining,
545		Inference, and Prediction, (Springer New York, 2013).
546	24.	Russell, W.R. et al. Impact of Diet Composition on Blood Glucose Regulation. Crit Rev Food
547		Sci Nutr 56 , 541-90 (2016).
548	25.	Jeong, Y. et al. A Review of Recent Evidence from Meal-Based Diet Interventions and Clinical
549		Biomarkers for Improvement of Glucose Regulation. Prev Nutr Food Sci 25, 9-24 (2020).
550	26.	Delahanty, L.M. et al. Effects of weight loss, weight cycling, and weight loss maintenance on
551		diabetes incidence and change in cardiometabolic traits in the Diabetes Prevention Program.
552		Diabetes Care 37 , 2738-45 (2014).
553	27.	Diabetes Prevention Program Research, G. et al. 10-year follow-up of diabetes incidence and
554		weight loss in the Diabetes Prevention Program Outcomes Study. <i>Lancet</i> 374 , 1677-86
555		(2009).
556	28.	Knowler, W.C. <i>et al.</i> Reduction in the incidence of type 2 diabetes with lifestyle intervention
557		or metformin. <i>N Engl J Med</i> 346 , 393-403 (2002).
558	29.	Papandonatos, G.D. <i>et al.</i> Genetic Predisposition to Weight Loss and Regain With Lifestyle
559		Intervention: Analyses From the Diabetes Prevention Program and the Look AHEAD
560		Randomized Controlled Trials. <i>Diabetes</i> 64, 4312-21 (2015).
561	30.	Taylor, R. Banting Memorial lecture 2012: reversing the twin cycles of type 2 diabetes.
562		t Med 30 , 267-75 (2013).
563	31.	Bell, K.J. <i>et al.</i> Impact of fat, protein, and glycemic index on postprandial glucose control in
564		type 1 diabetes: implications for intensive diabetes management in the continuous glucose
565	22	monitoring era. <i>Diabetes Care</i> 38 , 1008-15 (2015).
566	32.	Hansson, P. <i>et al.</i> Meals with Similar Fat Content from Different Dairy Products Induce
567		Different Postprandial Triglyceride Responses in Healthy Adults: A Randomized Controlled
568	22	Cross-Over Trial. J Nutr 149 , 422-431 (2019).
569	33.	Atkinson, F.S., Hancock, D., Petocz, P. & Brand-Miller, J.C. The physiologic and phenotypic
570 571		significance of variation in human amylase gene copy number. <i>Am J Clin Nutr</i> 108 , 737-748 (2018).
571	24	Gardner, C.D. <i>et al.</i> Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in
572	34.	Overweight Adults and the Association With Genotype Pattern or Insulin Secretion: The
573 574		DIETFITS Randomized Clinical Trial. JAMA 319 , 667-679 (2018).
575	35.	Viitasalo, A. <i>et al.</i> Genetic predisposition to higher body fat yet lower cardiometabolic risk in
576	55.	children and adolescents. Int J Obes (Lond) 43 , 2007-2016 (2019).
570	36.	Hughes, R.L., Kable, M.E., Marco, M. & Keim, N.L. The Role of the Gut Microbiome in
578	50.	Predicting Response to Diet and the Development of Precision Nutrition Models. Part II:
579		Results. Adv Nutr (2019).
580	37.	Lee, J.G. <i>et al.</i> Deep Learning in Medical Imaging: General Overview. <i>Korean J Radiol</i> 18 , 570-
581	57. 584 (2	
582	38.	Dubois, C. <i>et al.</i> Effects of graded amounts (0-50 g) of dietary fat on postprandial lipemia and
583	50.	lipoproteins in normolipidemic adults. <i>Am J Clin Nutr</i> 67 , 31-8 (1998).
584	39.	Garcia-Perez, I. <i>et al.</i> Objective assessment of dietary patterns by use of metabolic
585	55.	phenotyping: a randomised, controlled, crossover trial. <i>Lancet Diabetes Endocrinol</i> 5 , 184-
586		195 (2017).
587	40.	Zierer, J. <i>et al.</i> The fecal metabolome as a functional readout of the gut microbiome. <i>Nat</i>
588		Genet 50 , 790-795 (2018).
589		
FOO		

Methods

592 Study population, study design, recruitment criteria, meal challenges and Zoe app.

593 Study population

594 The PREDICT 1 study (Personalised Responses to Dletary Composition Trial) was a multinational study conducted between 5th June 2018 and 8th May 2019. The primary cohort was recruited at St. 595 596 Thomas' Hospital in London, UK and a validation cohort (that underwent the same profiling as in the 597 UK) assessed at Massachusetts General Hospital (MGH) in Boston, Massachusetts as described in the 598 detail in the protocol ⁴¹. In the UK, participants (target enrolment = 1,000) were recruited from the 599 TwinsUK cohort, an ongoing research cohort described elsewhere¹⁶ and online advertising (**Extended** 600 Data Figure 1a). In the US, participants (target enrolment = 100) were recruited through online advertising, research participant databases and Rally for Research (<u>https://rally.partners.org/</u>), an 601 602 online recruiting portal for research trials (Extended Data Figure 1b). Ethical approval for the study 603 was obtained in the UK from the Research Ethics Committee and Integrated Research Application 604 System (IRAS 236407) and in the US from the Institutional Review Board (Partners Healthcare IRB 605 2018P002078). The trial was registered on ClinicalTrials.gov (registration number: NCT03479866), as 606 part of the registration for the PREDICT Programme of research, which also includes 2 other study 607 protocol cohorts. The trial was run in accordance with the Declaration of Helsinki and Good Clinical 608 Practice.

509 Study participants were healthy individuals aged between 18-65 years and able to provide written 510 informed consent. Criteria used to assess eligibility are listed in **Extended Data Table 1.** Exclusion 511 criteria included; ongoing inflammatory disease; cancer in the last three years (excluding skin 512 cancer); long term gastrointestinal disorders including IBD or Coeliac disease (gluten allergy), but not 513 including IBS; taking the following daily medications: immunosuppressants, antibiotics within the 514 last three months; capillary glucose level of >12mmol/L (or 216 mg/dL), or Type I diabetes mellitus,

- or taking medications for type II diabetes mellitus; currently suffering from acute clinically diagnosed
- depression; heart attack (myocardial infarction) or stroke in the last 6 months; pregnant; vegan,
- 617 suffering from an eating disorder or unwilling to take foods that are part of the study.

618 Study design

- 619 1,002 generally healthy adults from the United Kingdom (UK) (non-twins, and identical
- 620 [monozygotic; MZ] and non-identical [dizygotic; DZ] twins) and 100 healthy adults from the United
- 621 States (US) (non-twins; validation cohort) were enrolled and completed baseline clinic

622 measurements. Key outcomes include postprandial metabolic responses (0-6h; blood triglyceride, 623 glucose and insulin concentrations) to sequential mixed-nutrient dietary challenges (containing 86g 624 carbohydrate and 53g fat at 0h; 71g carbohydrate and 22g fat at 4h) administered in a tightly 625 controlled clinic setting on day 1 (Figure 1). A second set of outcomes were assessed over the 626 subsequent 13-days at home. Lipemic and C-peptide responses (as a surrogate for insulin) to two 627 standard meals differing in fat and carbohydrate composition were assessed at home using dried 628 blood spot (DBS) assays collected at three postprandial time-points. Glycemic responses to eight 629 meals (seven in duplicate) of different macronutrient (fat, carbohydrate, protein and fiber) content 630 were assessed using continuous glucose monitors (CGM). In addition, participants wore physical 631 activity and sleep monitors for the duration of the study and provided stool samples for microbiome 632 profiling.

We selected specific timepoints and increments for triglyceride, glucose, insulin and C-peptide to reflect the different pathophysiological processes for each measure. To monitor compliance, all test meals consumed by participants were logged in the Zoe app (with an accompanying picture) and reviewed in real time by the study nutritionists. Only test meals that were consumed according to the standardized meal protocol were included in the analysis.

Baseline clinic visit (Day 1): Participants in the UK were mailed a pre-visit study pack with a stool
 collection kit and a health and lifestyle (amended Twins Research health and lifestyle questionnaire
 ⁴²and food frequency questionnaire (European Prospective Investigation into Cancer and Nutrition

(EPIC) Food-Frequency Questionnaire (FFQ)⁴³). In the US, minor modifications were made to the
health and lifestyle questionnaires to conform to a US population and the Harvard Semi-quantitative
FFQ, a validated US instrument, was substituted for the EPIC FFQ. Stool collection and

questionnaires were completed at home and returned to study staff at the baseline visit.

645 Participants were asked to refrain from exercise and to limit fat, fiber and alcohol intake for 24 hours 646 beforehand and to abstain from caffeine from 6pm the night before the baseline visit. Participants 647 arrived at 8:30am for their visit, having fasted from 9pm the night before, and were cannulated in 648 the forearm (antecubital vein) to collect a fasted blood sample, before being fitted with wearable 649 devices (continuous glucose monitor (CGM; Freestyle Libre Pro, Abbott, Abbott Park, IL, US) and 650 wrist-based triaxial accelerometer (AX3, Axivity, Newcastle, UK)). Heart rate and blood pressure 651 were measured using an automated blood pressure monitor while fasted (in triplicate, with mean of 652 second and third measurements recorded). Participant weight, height, hip and waist circumference 653 were measured using standard clinical techniques. Fasting blood glucose level was checked using 654 HemoCue Glucose 201 + System (Radiometer, Crawley, UK) or Stat Strip (Nova Biomedical, Waltham, 655 MA, US) in the UK and US, respectively.

Following the baseline blood draw, participants consumed a breakfast (muffins and milkshake at 0 min) and lunch (muffins at 240 min) test meal (**Supplemental Table 2**), each to be consumed within 10 minutes. Additional venous blood was collected via cannula at 15, 30, 60, 120, 180, 240, 270, 300 and 360 minutes. Participants had access to water to sip throughout the visit. Between blood sampling, participants were trained in how to complete the study at home, including when and how to consume standardised test meals, perform DBS, and use the Zoe study app. Upon completing their baseline visit, participants received all the components necessary to complete the home-phase.

664 *Home-phase (Days 2-14):* During the study home-phase, participants consumed multiple

standardised test meals for breakfast and lunch over a 9-11-day period, differing in macronutrient

666 composition (carbohydrate, fat, protein and fiber) while wearing the CGM and accelerometer.

Participants recorded all of their dietary intake and exercise on the Zoe study app throughout the study. DBS tests were completed on 4 days before and after test meals, as outlined in the online protocol⁴¹. Following completion of the home-phase, participants returned all study samples and devices to study staff via standard mail.

671

Test meal preparation, nutrient composition, timings and standardised participant test mealinstructions

674 Upon completing their baseline visit, participants received a home-phase meal pack containing test 675 meal components (nutrient composition; Supplemental Table 2) which they consumed according to 676 standardised instructions for breakfast and, on some days, lunch. Test meals consisted of either an 677 oral glucose tolerance test (OGTT; on 2 days) or muffins, which were consumed on their own or 678 paired with chocolate milk, protein shake, or commercial fiber bars and ordered according to one of 679 3 protocol groups described in **Supplemental Table 2.** Meal order for the 3 protocol groups was 680 randomised using Microsoft Access for each participant, using a 2-block randomisation and 1 non-681 randomised block.

682

683 Participants were instructed to fast for a minimum of 8 hours prior to consuming a test breakfast 684 meal, and to fast for 3 or 4 hours after meal consumption (depending on test meal; in protocol 1, 685 fasting period was 3 hours for Meal 5 and 4 hours for all other meals; in protocols 2 and 3, the 686 fasting period was 3 hours for all breakfast meals, excluding combinations of breakfast and lunch, 687 where fasting periods were 4 and 2 hours, respectively). They were advised to limit exercise and 688 drink only plain, still water during fasting periods. When fasting was completed, participants could 689 eat, drink and exercise as they liked for the rest of the day. Participants were asked to consume all 690 muffin-based meals within 10 minutes and the OGTT within 5 minutes and to notify study staff if this 691 was not achieved, in which case the data was excluded from analysis. If the participant chose to 692 accompany their home-phase muffin-based test meals with a tea or coffee (with up to 40ml of 0.1% fat cow's milk, but no sugar or sweeteners), they were instructed to consume this drink consistently,
in the same strength and amount, alongside all muffin-based test meals throughout the study.
Participants were instructed to not consume any food or drink other than water alongside the OGTT,
and to avoid physical activity during the 3-hour fasting period that followed it.

697

Test meals and any dietary intake consumed within fasting periods, including accompanying drinks, were recorded in the Zoe app by participants with the exact time at consumption and ingredient quantities so that compliance could be monitored by study staff. Only test meals that were completed according to instructions were included in analysis.

702

703 Test meals were prepared and packaged in the Dietetics Kitchen (Department of Nutritional 704 Sciences, King's College London, London, UK) using standard ingredients; plain flour, sugar, baking 705 powder, vanilla essence, milk, egg, salt, high-oleic sunflower oil, whey protein powder, chocolate 706 milkshake powder (Nesquik, Nestle, Gatwick, UK), and commercially available fiber bars (Chocolate 707 Fudge Brownie, Fiber One, General Mills, MN, US; Goodness Bar Apple & Walnut, The Food Doctor, 708 Hessle, UK). Test meals were shipped frozen, under temperature controlled conditions, to the US to 709 limit variability of the intervention. Participants were instructed to freeze their muffins at home and 710 defrost each set of muffins in the fridge the night before consuming them. Test meal drinks were 711 prepared by the participant at home by mixing pre-portioned powder sachets with long-life milk 712 provided (Meal 1, 220ml 0.1% fat milk; Meal 8, 200ml 1.6% fat milk). Powder sachets and fiber bars 713 were stored at room temperature until consumption. The OGTT (Meal 5) consisted of a pre-714 portioned powdered glucose sachet which participants mixed with 300ml water in the UK. In the US 715 participants were provided with pre-mixed OGTTs ready for consumption (Cat# 82028-512; VRW, 716 US).

717

718 Zoe study app and dietary assessment methodology

719 The Zoe app was developed to support the PREDICT 1 study by serving as an electronic notebook of 720 study tasks, a tool for recording all dietary intake and a portal for communication with study staff. 721 The app sent participants notifications and reminders to complete tasks at certain time-points, such 722 as when their test lunch meals and DBS were due, and asked participants to report their hunger and 723 alertness levels on visual analogue scales truncated from Flint et al⁴⁴. Participants were asked to log 724 in the app any exercise which would not be well captured by a wrist-affixed accelerometer, such as 725 cycling. Participants logged their full dietary intake using the app over the 14-day study period, 726 including all standardized test meals and free-living foods, beverages (including water) and 727 medications. Data logged into the app was uploaded onto a digital dashboard in real time and 728 reviewed and assessed for logging accuracy and study guideline compliance by study staff. 729 'Study staff trained all participants at their baseline clinic visit on how to accurately weigh and 730 record dietary intake through the Zoe study app, using photographs, product barcodes, product-731 specific portion sizes, and digital scales. Study nutritionists also reviewed food logging data by 732 comparing the photographs uploaded by subjects with the items they logged on the app. Any 733 uncertainties were clarified actively with the participant through the app messaging system or via 734 phone while the participant was on the study.

735

736 Protocol versions and amendments

Protocol amendments for the PREDICT study, post-commencement of the study and participant enrolment, are as follows: The first amendment (approved by UK IRAS 1st August 2018) allowed additional test meals to be included in the home-phase and participants' logging of gut transit time by using a Metabolic Challenge Breakfast (Meal 1) on the clinic day dyed blue with food coloring. The DBS protocol was also changed according to physiological peaks in biomarkers (triglyceride or C-peptide). Starting on 28 Aug 2018, triglyceride was measured on Days 2-3 at fasting, 300 and 360 minutes post-prandially, while C-peptide was quantified on Days 4-5 at 744 fasting, 30 and 120 minutes post-prandially as described for Protocol Group 2. A second saliva 745 sample collection was also added on the clinic day, at 30 minutes after the metabolic challenge 746 breakfast, to measure salivary amylase production post prandially and provide a comparison to 747 fasted amylase levels. The second amendment (approved by UK IRAS 2nd September 2018) was 748 a change in the lower BMI limit for eligibility to 16.5kg/m² (originally 20 kg/m²). Minor meal 749 changes were made, not requiring ethical approval, which resulted in Protocol Group 3 750 (implemented in January 2019). In the US, on 3 January 2019, the IRB approved an amendment 751 (PREDICT-US v2.0) to address meal changes introduced in the UK for Group 3 and to allow the 752 use of multiple CGMs on the same participant. No other major amendments to the intervention 753 protocol were made during the study period in the US.

754

755 Outcome variables and sample collection, handling and analysis

756 Dried blood spot collection, method validation and analysis.

757 <u>Dried blood spot collection:</u> Triglyceride and C-peptide were quantified from DBS tests completed by 758 participants at the baseline visit (at fasted baseline and 300 minutes post-breakfast; for method 759 validation) and on the first 4 days of the home-phase while consuming test meals (test timings and 760 associated meals are outlined in the online protocol ⁴¹).

761

The Zoe app sent participants reminders to complete their DBS tests at due times, which participants then logged in the app by recording the time at testing and a photo of the completed card for quality assessment by study staff. Test cards not meeting the quality protocol (multiple small spots or inadequate coverage) were not included in analysis. Test cards were stored in aluminium sachets with desiccant once completed and placed in the fridge at the end of the study day or until participants mailed them back to the study site. DBS cards were then frozen (-80 °C) and shipped for analysis (Vitas Analytical Services, Oslo, Norway). 769

Dried blood spot method validation: DBS C-peptide and triglyceride concentrations were validated
 during PREDICT, against venous serum concentrations collected during the baseline clinic visit at 0
 and 300 minutes post breakfast test meals. Correlations between the two methods were found to be
 high; for triglyceride (1,772 pairs) Pearson's r=0.94; for C-peptide (1,679 pairs) Pearson's r=0.91.

774

775 Quantification of total triglyceride from DBS: From the DBS sample, 2 punches were taken and 776 transferred into a HPLC vial and lipids extracted with methanol at 600 rpm and 25 °C for 3 hours. The 777 resulting extract was processed with a triglyceride kit (FUJIFILM Wako Chemicals GmbH, Neuss, 778 Germany) at 600 rpm and 37 °C for 2.5 hours and the reaction products were subsequently analyzed 779 by HPLC-UV. HPLC was performed with a HP 1260/1290 infinity liquid chromatograph (Agilent 780 Technologies, Palo Alto, CA, US) using UV detection. The analyte was separated from matrix 781 components on a 4.6 mm x 100 mm reversed phase column at 40 °C. A one-point calibration curve 782 was made from analysis of triglyceride standard after enzymatic reaction with the kit. The analytical 783 method is linear from 0.5-6 mmol/L with a quantification limit of 0.3 mmol/L. 784

Quantification of C-peptide from DBS: C-peptide in DBS were assayed using a Mercodia solid phase two-site enzyme immunoassay (ELISA; Mercodia AB, Uppsala, Sweden). Three spots were punched into the kit plate with anti-C-peptide antibodies bound to the well. Assay buffers were added and Cpeptide extracted from the spots at 4 °C. After washing, peroxidase-conjugated anti-C-peptide antibodies were added and after the second incubation and a washing step, the bound conjugate was detected by reaction with 3,3`,5,5`-tetramethylbenzidine (TMB). The reaction was stopped by adding acid to give a colorimetric endpoint that was read spectrophotometrically at 450 nm.

792 Stool sample collection, method validation and microbial analysis

793 Stool sample collection: Participants collected a stool sample at home prior to their clinical visit. 794 Samples were collected using the EasySampler collection kit (ALPCO, NH, US) into fecal collection 795 tubes containing DNA/RNA Shield buffer (Zymo Research, CA, US). Upon receipt in the laboratory, 796 samples were homogenised, aliquoted and stored at -80 °C in Qiagen PowerBeads 1.5 mL tubes 797 (Qiagen, Germany). The sample collection procedure was tested and validated internally comparing 798 different storage conditions (fresh, frozen, buffer), different DNA extraction kits (PowerSoilPro, 799 FastDNA, ProtocolQ, Zymo), and different sequencing technologies (16S rRNA and arrays), data not 800 shown.

801

802 Microbiome 16S rRNA gene sequencing and analysis: The DNA was isolated by QIAGEN Genomic 803 Services using DNeasy® 96 PowerSoil® Pro. Optical density measurement was done using 804 Spectrophotometer Quantification (Tecan Infinite 200). The V4 hyper-variable region of the 16S 805 rRNA gene was then amplified at Genomescan, Leiden, Netherlands. Libraries were sequenced for 806 300 bp paired-end reads using the Illumina NovaSeq6000 platform. In total, 9.6 Pbp were generated 807 and raw reads were rarefied to 360k reads per sample. Rarefied reads were analyzed using the 808 DADA2 pipeline ⁴⁵. Quality control of the reads was performed using the "filterAndTrim" function 809 from the DADA2 package truncating eight nucleotides from each read to remove barcodes, 810 discarding all reads with quality less than 20, discarding all reads with at least one N, and removing 811 the phiX Illumina spike-in. Only paired-end reads with at least 120 bp and with an expected DADA2 812 error less than 4 were retained for downstream analyses. Error rates were inferred from the cleaned 813 set of reads ("learnErrors" function) and used in the DADA2 algorithm ("mergePairs" function) for 814 merging the reads, after dereplication ("derepFastq" function). Merged reads were further 815 processed retaining only reads within 280 and 290 bp, representing the majority of the distribution 816 of the lengths. Reads were further processed to remove chimeras using the "removeBimeraDenovo" 817 function with a consensus method. Finally, taxonomy was assigned using the SILVA database

(version 132) using the "assignTaxonomy" function and requiring a minimum bootstrap value of 80
obtaining a table of relative abundances of operational taxonomic units (OTUs). To address the issue
of compositionality in the microbiome data set⁴⁶ the relative abundance values were normalized
using the (arcsin-sqrt) transformation as described in ⁴⁷. Measures of alpha diversity were computed
(see⁴⁷). The distributions of the Simpson and Shannon indices of alpha diversity on the transformed
16S abundance data are presented in Supplemental Table 4.

824

825 Venous blood sample collection

826 Participants came into the clinical research facilities at 8:30am and were cannulated in the forearm 827 antecubital vein. Venous blood was collected at 0 minutes (prior to a test breakfast) and at 9 time-828 points postprandially (15, 30, 60, 120, 180, 240, 270, 300, and 360 minutes). Plasma glucose was 829 analyzed from blood samples collected into fluoride oxalate tubes and centrifuged at 1900 q for 10 830 min at 4 °C. Serum C-peptide, insulin, triglyceride, fasting lipid profile, thyroid stimulating hormone, 831 alanine aminotransferase, and liver function panel were analyzed from blood samples collected into 832 gel separator serum tubes and allowed to stand at room temperature before centrifuging at 1900 g833 for 10 min at 4 °C. Samples were aliquoted and stored at -80 °C. Blood, for complete blood count 834 (CBC) analysis, was collected into EDTA tubes, kept at 4 °C and analyzed within 12 hours of 835 collection.

836

837 Serum biomarkers

In the UK, insulin, glucose, triglyceride and C-peptide analysis was conducted by Affinity Biomarkers
Labs (London, UK). Glucose and triglyceride analyses were conducted on a Siemens ADVIA 1800
using Siemens assay kits (Siemens Healthcare Diagnostics Ltd, Surrey, UK). Triglyceride was analyzed
using the ADVIA chemistry triglyceride method based on the Fossati three-step enzymatic reaction
with a Trinder endpoint. Glucose was analyzed using the ADVIA chemistry glucose oxidase (GLUO)

843 method (based on the modified method of Keston). C-peptide and insulin were analyzed using the 844 Siemens ADVIA Centaur XP systems using a two-site sandwich immunoassay. Complete blood count 845 (CBC) was measured by Viapath (London, UK) for the UK cohort using standard automated clinical 846 chemistry techniques. The inter-assay coefficient of variation for PREDICT samples analyzed by 847 Affinity were: insulin 3.4%, C-peptide 7.9%, triglyceride 3.7%, and glucose 2.6%. 848 In the US, CBC was established using fresh blood samples in the MGH Core Laboratory. Hb1AC tests 849 were performed by the MGH Diabetes A1c lab. Glucose, insulin, triglyceride, and C-peptide were conducted by Quest Diagnostics (Boston, MA) using standard automated clinical chemistry 850 851 techniques. 852 Upon completion of the US study, frozen serum and plasma samples were sent from the US to the 853 UK and the entire cohort had liver function panel, full lipids (TC, HDL-C LDL-C and triglyceride), 854 thyroid stimulating hormone and alanine aminotransferase measurements performed by Affinity 855 Biomarkers Labs. Details described elsewhere ⁴⁸.

856

857 Glucose using continuous glucose monitoring

858 Interstitial glucose was measured every 15 minutes using Freestyle Libre Pro continuous glucose 859 monitors (Abbott, Abbott Park, IL, US). Monitors were fitted by trained nurses on the upper, non-860 dominant arm at participants' baseline visit and covered with Opsite Flexifix adhesive film (Smith & 861 Nephew Medical Ltd, Hull, England) for improved durability, and worn for the entire study duration 862 (14 days). Data collected 12 hours and onwards after activating the device was used for analysis. For 863 a subgroup of participants (n=377), we fitted two monitors on their arms and calculated the 864 Coefficient of Variation (CV =11.75%) and correlation (r = 0.97) of their iAUC responses to 865 standardized meals (Extended Data Figure 2b).

866

867 Time points for analyses:

868 <i>Glucose:</i> The 2-hour glucose iAUC was used for both clinic and at-home analyse	e: The 2-hour glucose iA	as used for both	i clinic and at-home analyse
--	--------------------------	------------------	------------------------------

869 Insulin and C-peptide: C-peptide was measured at home as a surrogate for insulin secretion,

- 870 because the reliability of C-peptide measured from DBS is higher than that of insulin (see⁴⁹) and C-
- 871 peptide remains stable on paper filters for up to 6 months ⁴⁹. C-peptide was measured at 60 minutes
- 872 postprandially to coincide with the peak in C-peptide seen in healthy individuals in clinic, and again
- at 120 minutes to coincide with the strong decline in insulin level (Extended Data Figure 2c).
- 874 However, because previous genetic studies have tested the heritability of postprandial insulin at 120
- 875 minutes, this time point was included for our own heritability analyses (Figures 2b-c). All other
- analyses refer to the 1-hour rise for C-peptide.
- 877
- 878 Triglyceride: The rise in triglyceride at 6 hours postprandially (triglyceride...) was selected to

879 represent postprandial lipemic response from serum collected at clinic and home-based DBS tests.

880 This is a measure of lipemia most closely correlated with atherogenic lipoproteins compared to

iAUC). C and 4h triglyceride concentration (see. 50-52

882

883 Activity and sleep

Energy expenditure was measured using a triaxial accelerometer (AX3, Axivity, UK) fitted by nurses at the baseline visit on the non-dominant wrist and worn for the duration of the study (except during water-based activities, including showers and swimming). Accelerometers were programmed to measure acceleration at 50 Hz with a dynamic range of ±8 g (where g refers to local gravitational force equal to 9.8 m/s²). Non-wear periods were defined as windows of at least 1 hour with less than 13mg for at least 2 out of 3 axes, or where 2 out of 3 axes measured less than 50mg. Windows of sleep were measured using methods described elsewhere⁵³.

892 Genotyping

893 Whole genome genotyping was available for 241 individuals from the UK cohort from previous 894 TwinsUK studies. Genotyping was performed with the Illumina Infinium HumanHap610. Normalised 895 GWAS intensity data were pooled and genotypes called on the basis of the Illuminus algorithm. No 896 calls were assigned if the most likely call was less than a posterior probability of 0.95. Validation of 897 pooling was done by visual inspection of 100 random, shared SNPs for overt batch effects (none 898 were observed). SNPs that had a low call rate ($\leq 90\%$), Hardy-Weinberg p values $< 10^{-6}$ and minor 899 allele frequencies <1% were excluded, and samples with call rates <95% were removed. Genotype 900 imputations were performed to increase the coverage. Imputation of genotypes for all polymorphic 901 SNPs that passed the quality control stage were performed on the Michigan Imputation Server 902 (https://imputationserver.sph.umich.edu) using the 1000G Phase3 v5 reference panel⁵⁴. SNPs 903 previously reported to be associated with postprandial glycemia, triglyceride or insulin GWAS¹⁷⁻²⁰ 904 were extracted from the full set of genome wide genotypes using PLINK and tested for association 905 with postprandial measures using linear regression methods.

906 Processing of habitual diet information

907 UK nutrient intakes were determined using FETA software to calculate macro- and micro- nutrient
908 data⁴³. Submitted FFQs were excluded if greater than 10 food items were left unanswered, or if the
909 total energy intake estimate derived from FFQ as a ratio of the subject's estimated basal metabolic
910 rate (determined by the Harris-Benedict equation)⁴³ was more than two standard deviations outside
911 the mean of this ratio (<0.52 or >2.58).

913 Statistical analysis

914 Basic analyses

915	The descriptive characteristics of study participants are summarized in Supplemental Table 1
916	In order to reduce the dimension of the data, principal component analysis (PCAs) with orthogonal
917	transformation (varimax procedure) was applied to derive principal components (PC) representative
918	of individual characteristics (20 PCAs), microbiome (40 PCAs), meal composition (1 PCA), habitual
919	diet (5 PCAs) and meal context (5 PCAs) (see Supplemental Table 3 for full list of input variables). All
920	the necessary prerequisites of PC analysis including linearity, Kaiser–Meyer–Olkin measure of 0.88,
921	and the significant Bartlett's test of sphericity (p < 0.001) were met. Each participant received a
922	score for each category mentioned above. To investigate the association between each outcome
923	(iAUC, triglyceride $_{\text{\tiny Bhrdise}}$, C-peptide $_{\text{\tiny Bhrdise}}$) and our exposures (individual baseline characteristics,
924	microbiome (16S), meal content, habitual diet and meal context) multivariable regressions were
925	applied and R^2 reported. Further, we derived PCAs for the anthropometrics, biochemical/clinical
926	factors, physical activity and sleep features separately to investigate their role. Multi-collinearity for
927	the multiple linear regressions was assessed with variance inflation factors (VIF) at each step ⁵⁵ .
928	Multi-collinearity was considered high when the VIF was >10 ³⁸ . Receiver operating characteristic
929	(ROC) curves were constructed and the area under the curve (AUC) was calculated to assess the
930	discriminatory power of (fasting blood glucose vs. 2h glucose iAUC), (fasting triglyceride vs.
931	triglyceride $_{\text{Brrise}}$) and (fasting C-peptide vs. C-peptide $_{\text{Indiae}}$) to detect impaired glucose tolerance, and
932	ASCVD 10 year risk (70% applied as a cut-off point). Values of AUC range from 0.5 and 1, with 0.5
933	indicating no discrimination, and 1 indicating perfect discrimination (2). A p-value \leqslant 0.05 was
934	considered statistically significant. All analyses were performed using R (version 3.4.2 R Core Team
935	(2017)).

936 Meal composition

937 To estimate macronutrient effects on glycemic response, we fitted a multivariate regression model
938 with carbohydrates, fats, fiber and protein as predictors on meals 1, 2, 4, 5, 6, 7 and 8.

- 939 Multicollinearity was assessed for these predictors through VIF and we concluded that it was non
- 940 existent (VIF < 10). The regression coefficients were all significant (p < 0.001) with values -79.23
- 941 mmol/L*s, -142.41 mmol/L*s and -185.49 mmol/L*s for fat, fiber and protein respectively, after
- 942 having adjusted by carbohydrates.

943 Heritability and ACE model

944 To estimate the heritability, we analyzed the data according to the classical ACE model. In this 945 model, heritability is an approximation of the relative importance of additive genetic differences for 946 variance of postprandial responses in the population⁵⁶. Shared or familial environmental influences 947 reflect experiences that contribute to twin similarity. Non-shared or individual-specific 948 environmental influences refer to the contribution of environmental experiences not shared by 949 family members. Information concerning shared genetic and environmental influences is best 950 estimated by structural equation modelling techniques that fit models of twins by zygosity in order 951 to describe the 154 causes of the variance in OA. Therefore, the total variance in the trait can be 952 partitioned into genetic variance (A), shared (familial) environmental variance (C), and individual-953 specific environmental variance (E). The level of statistical significance was set at p<0.05 in all 954 analyses, and the R software (version 3.0.2) together with the "mets" (Multivariate Event Times) 955 package (https://rdrr.io/cran/mets/src/R/methodstwinlm.R) was used for all statistical analyses. 956

957 Meal ranking

Six different type of meals were ranked for each individual as being the one with the highest glucose
2h iAUC for that person (rank 6), the one with the second highest glucose iAUC (rank 5).....down the
the one with the lowest glucose 2h iAUC (rank 1). The distribution of these "in-person rankings" is
presented in Extended Data Figure 3.

963 Multilinear ANOVA to assess role of individualized responses to meals

- 964 The different sources of variation in glycemic response for Meal 2,3,4,6 and 8 (described in
- 965 **Supplemental Table 3**) were analysed using the Multilevel Linear ANOVA⁴⁰ model
- 966 and were analysed using a multilevel (hierarchical) linear Bayesian ANOVA model as described by
- 967 Gelman and Hill⁵⁷.
- 968 The different sources of variation in glycemic response for Meal 2,3,4,6 and were analysed using a
- 969 multilevel (hierarchical) Linear Bayesian ANOVA model as described by (Gelman & Hill 2007).
- 970
- 971 Hierarchical Bayes models can accommodate non-normal dependent variables that are difficult to
- 972 incorporate in classical ANOVA and multilevel linear models . The approach consists of sub-models at
- 973 two levels: at level 1 the parameters of individuals, meals and person-meal interactions, and at level
- 974 2 the moments of the distributions from which level 1 parameters are drawn. Level 2 imposes some
- 975 homogeneity on level 1 parameters, for example
- 976

977 $a_m \sim N(0, a_a^2)$ i.e. the meal terms are are distributed normally with the same standard deviation

- 978 *a*_a, ensuring homogeneity.
- 979 $a_a \sim HalfCauchy(5)$ i.e. the standard deviation of the above distribution has a particular prior (a 980 half cauchy distribution with a scale factor of 5) -
- 981 The other terms ($\{3_p, y_{m,p}, E_{m,p,k}, E_{m,p,k,n}$) have similar hierarchical distributions (though the
- standard deviations of $E_{m,p,k}$, $E_{m,p,k,n}$ have uniform prior as opposed to a half cauchy).
- 983 The parameters at both levels (i.e. all the a_m 's and a_a and analogously for the other parameters)
- 984 are sampled using an Markov Chain Monte-Carlo routine in pymc3 ⁵⁸ and we plot the sampled values
- 985 of a_a , a_{β} , a_y , a_E and a_{E_n} in Figure 6b.

$$log(iAUC) = y_{m,p,k,n} = \alpha_m + \beta_p + \gamma_{m,p} + \epsilon_{m,p,k} + \epsilon_{m,p,k,n}$$
986

987 where:

- 988 $-log(iAUC) = y_{m,p,k,n}$: the 2 hour iAUC for person p, eating meal m, for the k th time measured on
- 989 cgm *n* (given the availability of data with 2 CGMs for a subset as described in below.
- 990 the 2 hour iAUC for person *p*, eating meal *m*, for the *k* th time measured on cgm *n* (given that we
- 991 have 2 cgms for many people)
- 992 a_m : meal content (across all people) for meal *m*, e.g. high and low carbohydrate meals
- 993 $\{3_p:$ individual glucose scaling (across all meals) for person p, e.g. overall high and low responding 994 people
- 995 $-y_{m,p}$: the meal-specific response for individual p to meal m, e.g. a specific person responds
- 996 particularly strongly to a specific meal
- 997 E m.p.k.n : error stemming from the cgm (participants selected for this analysis wore 2 CGM devices,
- so *n* indexes the device providing the measurement)
- 999 $E_{m,p,k}$: other sources of variation, including meal timing, exercise, sleep and circadian rhythm
- 1000 This Bayesian ANOVA model is a Bayesian hierarchical model attempts to explain the observed
- 1001 log(iAUC) of a meal as a sum of categorical terms., i.e. individuals are not classified according to any
- 1002 characteristics but are included as unique individuals with log(iAUC 2h glucose) for various different
- 1003 meals. If this was an extended Glycemic Index model it would correspond to expressing the
- 1004 log(iAUC) as the sum of a meal term (analogous to the glycemic load of the meal) and an
- 1005 individualized term. This "individual glucose scaling" is not a linear function of a person's
- 1006 characteristics (such as age, sex or BMI) but rather it is how each individual ranks overall given the
- 1007 log(iAUC) values for the various meals. This allowed us to test whether there was an interaction term
- 1008 between meals and persons, i.e. an individualized response component to particular meals that was
- 1009 not merely due to a person being a high, average or low responder and to a meal having on average
- 1010 a higher glycemic response (e.g. OGTT) than another meal (e.g. a high fat muffin). Given the

1011 availability of data concerning repeated occurrences of a person eating a particular meal and 1012 multiple CGMs measurements for the same meal we were able to extend the model to include a 1013 person-meal interaction and a CGM error and, analogously, infer the error due to the CGMs and the 1014 degree to which a person's response to a particular meal is consistently higher or lower than one 1015 would expect from the glycemic index model .i.e. a personalized glycemic load. The person-meal 1016 interaction effects allow different people to have different ordering of glycemic responses to meals, 1017 so one person might respond more strongly to meal A than meal B, whilst another person might 1018 respond more strongly to meal B than meal A. Figure 6c shows show 50% and 95% intervals on 1019 standard deviations of the effects in the model. These can be approximately interpreted as percent 1020 increase (or decrease) in iAUC contributed by the various effects in the model.

1021

1022 CGM repeatability.

A subset of participants (n=483) wore two continuous glucose measurement devices simultaneously,
 providing duplicate measurements for the meals they consumed and therefore allowing us to
 distinguish CGM error from unexplained sources of variation. Postprandial glucose measurements
 for 3280 meals eaten collectively by 483 participants from UK were used in this analysis. (Extended
 Data Figure 2b).

1028

1029 Computation of clinical indices

1030 Atherosclerotic Cardiovascular Disease 10 year risk: (AHA/JACC ASCVD 10 year risk) The 10-year

1031 atherosclerotic cardiovascular disease (ASCVD) ⁵⁹ risk score is a gender and race specific single

1032 multivariable risk assessment tool used to estimate the 10-year CVD risk of an individual, and has

1033 clinically replaced the Framingham-10 year cardiovascular risk score. It is based on the age, sex,

1034 ethnicity, total and HDL cholesterol, systolic blood pressure, smoking status, use of blood pressure

1035 lowering medications, and the presence of type 2 diabetes (T2D).

1036 *Impaired glucose tolerance:* We used the standard definition from the American Diabetes

Association ⁶⁰ (Fasting plasma glucose < 7.0 mmol/l and OGTT 2-hour value >= 7.8 mmol/l but < 11.1
 mmol/l).

1039

1040 Validation of Machine learning model cross validation and difference (Bland-Altman plots)

- 1041 To further illustrate the reliability of the machine learning predictions, we conducted a leave-one-
- 1042 out cross validation procedure and generated Bland-Altman plots to analyze the agreement
- 1043 between two. To generate the Bland-Altman plots we used the Predict UK and US data showing
- 1044 Predicted vs Measured postprandial responses. We generated Bland-Altman plots for predicted and
- 1045 measured postprandial responses for each biomarker (Triglycerides, C-peptide and Glucose).
- 1046 (Extended Data Figure 4a).

1047 Leave-one-out cross-validated Pearson R scores in Predict UK

1048 To perform k-fold cross validation, the entire dataset is split into k groups. Treating each group as a

- 1049 test set and the remaining groups as the training set, the model is fitted k times. The Pearsons's R
- 1050 between the values predicted by the fitted models and the measured values in the test sets is used
- as the metric for model evaluation, which we refer to as the cross-validated Pearson-R.

1052

- 1053 The special case, where k is the size of the dataset, is referred to as leave-one-out cross-validation,
- 1054 and we refer to the corresponding evaluation metric as leave-one-out cross-validated Pearson R. The
- 1055 machine learning models for the three biomarkers of interest were evaluated using the
- 1056 aforementioned metric and are reported in the Extended Data Figure 4b . These scores are similar to
- 1057 the cross-validated 5-fold scores in the main text.


1058


1059


1061 Methods References:


1062		
1063	41.	Berry S, D.D., Linenberg I, Wolf J, Hadjigeorgiou G, Davies R, Al Khatib H, Hart D, Surdulescu
1064		G, Yarand D, Nessa A, Sheedy A, Vijay A, Asnicar, Segata N, Chan A, Franks P, Valdes A,
1065		Spector T. Personalised REsponses to Dietary Composition Trial (PREDICT): an intervention
1066		study to determine inter-individual differences in postprandial response to foods. <i>Protocol</i>
1067		Exchange (2020).
1068	42.	Verdi, S. <i>et al.</i> TwinsUK: The UK Adult Twin Registry Update. <i>Twin Res Hum Genet</i> , 1-7
1069		(2019).
1070	43.	Mulligan, A.A. <i>et al</i> . A new tool for converting food frequency questionnaire data into
1071	101	nutrient and food group values: FETA research methods and availability. <i>BMJ Open</i> 4 ,
1072		e004503 (2014).
1073	44.	Flint, A., Raben, A., Blundell, J.E. & Astrup, A. Reproducibility, power and validity of visual
1074	• • •	analogue scales in assessment of appetite sensations in single test meal studies. <i>Int J Obes</i>
1075		Relat Metab Disord 24 , 38-48 (2000).
1076	45.	Callahan, B.J. <i>et al.</i> DADA2: High-resolution sample inference from Illumina amplicon data.
1077	131	<i>Nat Methods</i> 13 , 581-3 (2016).
1078	46.	Gloor, G.B., Wu, J.R., Pawlowsky-Glahn, V. & Egozcue, J.J. It's all relative: analyzing
1079		microbiome data as compositions. Ann Epidemiol 26 , 322-9 (2016).
1080	47.	Thomas, A.M. <i>et al.</i> Metagenomic analysis of colorectal cancer datasets identifies cross-
1080		cohort microbial diagnostic signatures and a link with choline degradation. <i>Nat Med</i> 25 , 667-
1081		678 (2019).
1082	48.	Soininen, P., Kangas, A.J., Wurtz, P., Suna, T. & Ala-Korpela, M. Quantitative serum nuclear
1085	40.	magnetic resonance metabolomics in cardiovascular epidemiology and genetics. <i>Circ</i>
1085		Cardiovasc Genet 8, 192-206 (2015).
1085	49.	Johansson, J., Becker, C., Persson, N.G., Fex, M. & Torn, C. C-peptide in dried blood spots.
1080	45.	Scand J Clin Lab Invest 70 , 404-9 (2010).
1087	50.	Samson, C.E., Galia, A.L., Llave, K.I., Zacarias, M.B. & Mercado-Asis, L.B. Postprandial Peaking
1088	50.	and Plateauing of Triglycerides and VLDL in Patients with Underlying Cardiovascular Diseases
1005		Despite Treatment. Int J Endocrinol Metab 10 , 587-93 (2012).
1090	51.	Madhu, S., Sinha, B., Aslam, M., Mehrotra, G. & Dwivedi, S. Postprandial triglyceride
1091	51.	responses and endothelial function in prediabetic first-degree relatives of patients with
1092		diabetes. J Clin Lipidol 11 , 1415-1420 (2017).
1094	52.	Nakamura, A. <i>et al.</i> Different postprandial lipid metabolism and insulin resistance between
1094	52.	non-diabetic patients with and without coronary artery disease. <i>J Cardiol</i> 66 , 435-44 (2015).
1095	53.	van Hees, V.T. <i>et al.</i> Estimating sleep parameters using an accelerometer without sleep
1090	55.	diary. Sci Rep 8 , 12975 (2018).
1097	54.	Eitel, I. <i>et al.</i> Genome-wide association study in takotsubo syndrome - Preliminary results
1098	54.	and future directions. Int J Cardiol 236 , 335-339 (2017).
1100	55.	Slinker, B.K. & Glantz, S.A. Multiple regression for physiological data analysis: the problem of
1100	55.	multicollinearity. Am J Physiol 249 , R1-12 (1985).
1101	56.	Purcell, S. Variance components models for gene-environment interaction in twin analysis.
1102	50.	Twin Res 5 , 554-71 (2002).
1103	57.	Gelman, A. & Hill, J. Data analysis using regression and multilevel/hierarchical models, xxii,
1104	57.	625 p. (Cambridge University Press, Cambridge ; New York, 2007).
1105	58.	Salvatier, J., Wiecki, T.V. & Fonnesbeck, C. Probabilistic programming in Python using
1100	50.	PyMC3. Peerj Computer Science (2016).
1101		


- 110859.Goff, D.C., Jr. *et al.* 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a1109report of the American College of Cardiology/American Heart Association Task Force on
- 1110 Practice Guidelines. *Circulation* **129**, S49-73 (2014).
- 1111 60. American Diabetes, A. 2. Classification and Diagnosis of Diabetes. *Diabetes Care* **39 Suppl 1**,
 1112 \$13-22 (2016).















b











Exte nd ed Data Figure 1. Consort Diagrams for (a) UK and (b) US populations in the PREDICT 1 study.

Assessed for eligibility (n=1270)

a

Excluded from enrolment (n=268)

Assessed for eligibility (n=355)

b

Enro lled(n=1002)

• Withdrew (n=20)

• Lost to follow-up (n=15)

Enrolled(n=IOO)

Successfully completed the study (n=967)

Successfully completed the study (n=95)

Excluded from enrolment (n=255)

- Withdrew (n=4) ٠
- Lost to follow-up (n=1) •


Extended Data Figure 2. Repeatability in the PREDICT 1 study

a. Intraclass co rrelat ions


1 study, n = 1,036.

Metabolic outcome	num meals	Timepoint/ traitICC	95%C
TG	648	fa st ing	0.670.60 - 0.72
		Sh	0.660.60 - 0.72
		6h	0.730.68 - 0.78
		fasting-Sh rise	0.410.32 - 0.49
		fasting-6h rise	0.460.37 - 0.54
2lucose	8038	2h-iAUC	0.74 0.72 -0.75
c-peptide	626	fasting	0.720.66 - 0.77
		0.Sh	0.560.47 - 0.64
		2h	0.710.64 - 0.76
		fasting-0.S h rise	0.470.37 - 0.56
		fasting-2h rise	0.620.54 - 0.69


b. Pea rso n's correla tion and CV of 2h-iAUCs measured w it h two monito rs worn by the same participant (n=377). P-va lue from two-s ide d t-



c. Mean and standard error of fastingand postprandia ls e rum insulin and C-peptide concentrations during the clinic visit in the PREDICT




Extended Data Figure 3. Frequency distribution of in-person ranking for 6 of meals shown in Figure 6a (High fat 40g = meal 7, High protein = meal 8, UK average= meal 2, High carb = meal 4, OGTT = meal 5, Uk avgat lunch = meal 2). n=1102 participants



Extended Data Figure 4. Machine Learning comparisons, cross validat ion and repeatability

a. Bland-Alt man plots comparing predict ed and measured postprandial responses in TG, glucose and C-peptide using UK and US dat a. The sample sizesused n=number of meals: tri glyceride UK: n=958 US: n=91; C-peptide UK: n=957 US: n=93; Glucose UK:n=I I SSO US : n1200



b. Leave-one-out cross-validated Pearson R scores in PREDICT UK. 5-fold cross validation for Triglyceride 6 hour rise on n=958 meals, for Glucose2hiAUCon n=I I,550 meals, p-values shown for two-sided t-test

UK dat a set TG6h rise	Glucose;Au co-2h	
Leave-one-out 0.49, p = 2.03e - 56	0.77, p = 0.0	

c. comparison of models using repeat meals vs not using them

individual glucose scaling estimat e using all repeat meals : 18.7%changein glucose2hiAUC95%Cl [17.9-19.5%] indivdiual usi ng onlya si nglemeal from each set (one OGTT, one high carb, one high fatetc). 18.2%changein glucose2hiAUC95%CI [17.2-19.2%].




Table number	Title
S Table 1	Study eligibility criteria & descriptive baseline characteristics
S Table 2	Test meal nutritional composition and ordering
S Table 3	Proportion of postprandial response variances explained by individual characteristics
S Table 4	ACE heritability models, SNPs and 16S sequencing
S Table 5	Machine Learning Input Features